Innovative Breakthrough: Chinese Team Creates Novel CAR-T Cells Using CRISPR/Cas9 Technology
🔬 Innovative Breakthrough: Chinese Team Creates Novel CAR-T Cells Using CRISPR/Cas9 Technology 🔬
Nature
The clinical research achievements conducted by Professor Huang He’s team from the First Affiliated Hospital of Zhejiang University School of Medicine have been published online in the top international journal Nature under the title “Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL.”
In the field of CAR-T cells, we face numerous challenges. However, the collaboration between Professor Liu Mingyao’s team and Director Huang He’s team has introduced the innovative CRISPR/Cas9 gene editing technology into CAR-T therapy, bringing us unprecedented breakthroughs. They precisely utilized CRISPR/Cas9 technology to remove the “brake” PD1 from T lymphocytes and inserted the targeted CD19 CAR molecule for tumor cells, creating a brand-new non-viral targeted integration CAR-T cell (PD1-19bbz).
💡 Analyzing the Scientific Principles behind the Technology 💡
CRISPR/Cas9 can be likened to a “gene editing scissors,” with PD1 being the “brake” on T cells. By precisely removing the PD1 locus with the “scissors” and inserting the “GPS navigation system” CD19 CAR molecule at the same position, we successfully eliminated the “brake” of CAR-T cells, turning them into efficient killers targeting tumors.
🧬 Groundbreaking Clinical Validation 🧬
Through rigorous clinical studies, we have confirmed the safety and efficacy of PD1-19bbz. Whether in tumor cells with high or low PD-L1 expression, PD1-19bbz has demonstrated more powerful and durable killing effects. What’s more exciting is that our research indicates PD1-19bbz achieves a 100% objective response rate and an 87.5% complete response rate in treating refractory relapsed lymphoma patients.
🌟 Pioneering a New Era in CAR-T Cell Therapy 🌟
This groundbreaking achievement brings new hope to CAR-T cell therapy. We have successfully established a brand-new CAR-T cell technology platform, providing a safer and more effective option for the treatment of refractory relapsed lymphoma and other diseases. This also signifies the leading position of Chinese scholars in the field of CAR-T cell research and development internationally.
💬 Expert Evaluation 💬
Professor Justin Eyquem from the University of California and Senior Editor Victoria Aranda from Nature highly praised our achievements: “This inspiring result demonstrates the excellent clinical safety and efficacy of this CAR-T therapy.”
We will continue to dedicate ourselves to advancing CAR-T cell therapy, bringing hope and health to more patients. Stay tuned for our progress!
🧶You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address:
🌈🌈📩doctor.huang@globecancer.com🌈🌈,
or click on the ☎️WhatsApp+8613717959070☎️ icon on the homepage.
The Medical Department will contact you as soon as they receive the reports.
#CARTCells #CRISPR #ScientificBreakthrough #CancerTreatment